MARK2 and neoplasm: Sorafenib is an oral multitarget multikinase inhibitor that can target serine/threonine kinases and receptor tyrosine kinases on tumor cells and tumor blood vessels and has the dual effect of simultaneously inhibiting tumor cell proliferation and angiogenesis [33].